These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 33453716)

  • 1. Glomerular hyperfiltration with hyperglycemia in the spontaneously diabetic Torii (SDT) fatty rat, an obese type 2 diabetic model.
    Sano R; Ishii Y; Yamanaka M; Yasui Y; Kemmochi Y; Kuroki F; Sugimoto M; Fukuda S; Sasase T; Miyajima K; Nakae D; Ohta T
    Physiol Res; 2021 Mar; 70(1):45-54. PubMed ID: 33453716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of hyperglycemia on diabetic complications in obese type 2 diabetic SDT fatty rats: effects of SGLT inhibitor phlorizin.
    Katsuda Y; Sasase T; Tadaki H; Mera Y; Motohashi Y; Kemmochi Y; Toyoda K; Kakimoto K; Kume S; Ohta T
    Exp Anim; 2015; 64(2):161-9. PubMed ID: 25736710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute and Direct Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glomerular Filtration Rate in Spontaneously Diabetic Torii Fatty Rats.
    Takakura S; Takasu T
    Biol Pharm Bull; 2019; 42(10):1707-1712. PubMed ID: 31582658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
    Shin SJ; Chung S; Kim SJ; Lee EM; Yoo YH; Kim JW; Ahn YB; Kim ES; Moon SD; Kim MJ; Ko SH
    PLoS One; 2016; 11(11):e0165703. PubMed ID: 27802313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
    Vallon V; Gerasimova M; Rose MA; Masuda T; Satriano J; Mayoux E; Koepsell H; Thomson SC; Rieg T
    Am J Physiol Renal Physiol; 2014 Jan; 306(2):F194-204. PubMed ID: 24226524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats.
    Takakura S; Toyoshi T; Hayashizaki Y; Takasu T
    Life Sci; 2016 Feb; 147():125-31. PubMed ID: 26829386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of insulin therapy on renal changes in spontaneously diabetic Torii rats.
    Ohta T; Matsui K; Miyajima K; Sasase T; Masuyama T; Shoda T; Koizumi H; Shinohara M; Matsushita M
    Exp Anim; 2007 Oct; 56(5):355-62. PubMed ID: 18075195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of the sodium-glucose cotransporter type-2 inhibitor dapagliflozin on glomerular filtration rate in healthy cats.
    Gal A; Burton SE; Weidgraaf K; Singh P; Lopez-Villalobos N; Jacob A; Malabu U; Burchell R
    Domest Anim Endocrinol; 2020 Jan; 70():106376. PubMed ID: 31585313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
    van Bommel EJM; Muskiet MHA; van Baar MJB; Tonneijck L; Smits MM; Emanuel AL; Bozovic A; Danser AHJ; Geurts F; Hoorn EJ; Touw DJ; Larsen EL; Poulsen HE; Kramer MHH; Nieuwdorp M; Joles JA; van Raalte DH
    Kidney Int; 2020 Jan; 97(1):202-212. PubMed ID: 31791665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salt loading with unilateral nephrectomy accelerates decline in glomerular filtration rate in the hypertensive, obese, type 2 diabetic SDT fatty rat model of diabetic kidney disease.
    Shinozaki Y; Katayama Y; Yamaguchi F; Suzuki T; Watanabe K; Uno K; Tsutsui T; Sugimoto M; Shinohara M; Miyajima K; Ohta T
    Clin Exp Pharmacol Physiol; 2022 Apr; 49(4):492-500. PubMed ID: 35066915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiological analysis of female Spontaneously Diabetic Torii fatty rats.
    Ishii Y; Ohta T; Sasase T; Morinaga H; Ueda N; Hata T; Kakutani M; Miyajima K; Katsuda Y; Masuyama T; Shinohara M; Matsushita M
    Exp Anim; 2010; 59(1):73-84. PubMed ID: 20224171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin.
    Nørgaard SA; Briand F; Sand FW; Galsgaard ED; Søndergaard H; Sørensen DB; Sulpice T
    Eur J Pharmacol; 2019 Oct; 860():172537. PubMed ID: 31310751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
    Domon A; Katayama K; Sato T; Tochigi Y; Tazaki H; Suzuki H
    PLoS One; 2021; 16(5):e0251135. PubMed ID: 33945582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockout of Na
    Song P; Huang W; Onishi A; Patel R; Kim YC; van Ginkel C; Fu Y; Freeman B; Koepsell H; Thomson S; Liu R; Vallon V
    Am J Physiol Renal Physiol; 2019 Jul; 317(1):F207-F217. PubMed ID: 31091127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dapagliflozin attenuates early markers of diabetic nephropathy in fructose-streptozotocin-induced diabetes in rats.
    Oraby MA; El-Yamany MF; Safar MM; Assaf N; Ghoneim HA
    Biomed Pharmacother; 2019 Jan; 109():910-920. PubMed ID: 30551545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
    De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
    Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Pharmacological Responses to an Anti-diabetic Drug in a New Obese Type 2 Diabetic Rat Model.
    Murai Y; Ohta T; Tadaki H; Miyajima K; Shinohara M; Fatchiyah F; Yamada T
    Med Arch; 2017 Dec; 71(6):380-384. PubMed ID: 29416195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of sodium glucose linked cotransporter-2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus.
    Hare GMT; Zhang Y; Chin K; Thai K; Jacobs E; Cazorla-Bak MP; Nghiem L; Wilson DF; Vinogradov SA; Connelly KA; Mazer CD; Evans RG; Gilbert RE
    Physiol Rep; 2021 Jun; 9(12):e14890. PubMed ID: 34184431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes-associated complications in Spontaneously Diabetic Torii fatty rats.
    Matsui K; Ohta T; Oda T; Sasase T; Ueda N; Miyajima K; Masuyama T; Shinohara M; Matsushita M
    Exp Anim; 2008 Apr; 57(2):111-21. PubMed ID: 18421173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sodium-glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice.
    Li Z; Murakoshi M; Ichikawa S; Koshida T; Adachi E; Suzuki C; Ueda S; Gohda T; Suzuki Y
    FEBS Open Bio; 2020 Dec; 10(12):2761-2770. PubMed ID: 33098615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.